Impact Biomedical Inc. (AMEX:IBO) Implements Reverse Stock Split Ahead of Zoar Ltd. Merger

• Reverse Stock Split: Impact Biomedical Inc. (AMEX:IBO) is executing a 1-for-12.62 reverse stock split on September 23, 2026, to consolidate shares without altering total investor value.
• Strategic Merger: This corporate action is a crucial step in facilitating a planned merger with Zoar Ltd., with a Form F-4 registration statement filed with the U.S. Securities and Exchange Commission (SEC).
• Share Exchange Clarification: Post-split, each share of Impact Biomedical Inc. will be exchanged for one share of Zoar Limited, correcting a previous 1-for-4 announcement.

Impact Biomedical Inc. (AMEX:IBO), a key player in the biomedical sector, recently saw its stock performance improve. The company's stock is currently trading at $0.58, reflecting a daily increase of 16.87%. This brings the company's total value, or market capitalization, to approximately $62.75 million. Recent trading volume reached 175,325 shares, with its 52-week range spanning from $0.37 to $0.83, indicating significant investor interest.

Looking ahead, Impact Biomedical Inc. is set to execute a 1-for-12.62 reverse stock split on September 23, 2026. This corporate action means that for every 12.62 shares an investor holds, they will be consolidated into a single, higher-priced share. For clarity, this equates to receiving 50 shares for every 631 owned. Importantly, this share consolidation does not alter the total shareholder value of an investor's holding.

The Board of Directors of Impact Biomedical Inc. approved this reverse stock split as a strategic move to facilitate a planned merger with Zoar Ltd. This business combination is a significant step for both entities. Following the split, Impact Biomedical Inc. stock will continue its trading on the NYSE American Exchange under its existing symbol, though it will be assigned a new CUSIP number.

To further advance the merger completion, a Form F-4 registration statement has been filed with the U.S. Securities and Exchange Commission (SEC). This regulatory filing is a critical requirement for the business combination involving Zoar Limited. The finalization of the merger is contingent upon the SEC declaring the registration effective and the granting of all necessary regulatory approvals, ensuring full investment compliance.

Impact Biomedical Inc. also issued a correction concerning the merger's exchange terms. Post-reverse split, each share of Impact Biomedical Inc. will be exchanged for one share of Zoar Limited. This update clarifies a previous announcement that had incorrectly stated a 1-for-4 exchange ratio, providing more accurate and transparent shareholder information regarding the merger.